文献速递乳腺外科

老年cT2N0激素受体阳性HER2阴性乳腺癌前哨淋巴结活检影响有限

Limited impact of sentinel lymph node biopsy in older women with cT2N0 hormone-positive human epidermal growth factor receptor 2-negative breast cancer.
PubMed 文献 · Surgery · 2026-09-03

该单中心回顾性研究纳入2019至2023年113例≥65岁cT2N0激素受体阳性/HER2阴性乳腺癌患者,评估前哨淋巴结活检对辅助治疗决策的影响。结果显示31%患者pN1,仅2例因淋巴结状态改变化疗决策,多数淋巴结阳性者未接受区域淋巴结放疗,支持选择性个体化腋窝分期。

要点

  • ≥65岁cT2N0激素受体阳性/HER2阴性乳腺癌中,前哨淋巴结活检较少影响辅助治疗。
  • pN1占31%,仅2例化疗决策由淋巴结状态决定。
  • 淋巴结阳性者多数未接受区域淋巴结放疗。

核心结论

  • 在≥65岁cT2N0激素受体阳性/HER2阴性乳腺癌女性中,前哨淋巴结活检不常影响辅助治疗管理。

研究设计与样本

  • 单中心回顾性综述,纳入2019至2023年连续治疗的113例≥65岁cT2N0激素受体阳性/HER2阴性乳腺癌患者。

主要发现

  • 113例中35例(31%)为pN1,2例(1.8%)为pN2-3。
  • 37例病理淋巴结阳性患者中15例接受区域淋巴结放疗,其余未接受。
  • 中位随访3.1年,9例(8%)复发;4例复发的病理淋巴结阳性患者均内分泌治疗不依从。

关键数值与推荐

  • pN1占31%,pN2-3占1.8%。
  • pT1肿瘤淋巴结阳性率低于pT2(8% vs 31%,P = .035),pT2亚组间无差异(P = .864)。
  • 区域淋巴结放疗用于37例病理淋巴结阳性中的15例。

临床怎么用

  • 对≥65岁cT2N0激素受体阳性/HER2阴性乳腺癌患者,可考虑选择性省略前哨淋巴结活检,结合基因组检测和个体化评估制定辅助治疗方案。

局限性

  • 单中心回顾性设计,样本量有限,随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Consensus guidelines support selective omission of sentinel lymph node biopsy for axillary staging in older women with early stage, biologically favorable breast cancer; however, applicability to clinical T2 disease remains unclear. We evaluated the impact of sentinel lymph node biopsy on adjuvant treatment decisions in women ≥65 years with cT2N0 hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. METHODS: A single-institution retrospective review included consecutive patients treated from 2019 to 2023. Clinicopathologic features, adjuvant therapy decisions, and outcomes were analyzed. RESULTS: Among 113 patients, 35 (31%) had pN1 disease, and 2 (1.8%) had pN2-3 disease. Final pathologic tumor size was pT1 in 25 patients (22.1%), 2.1-3.0 cm in 48 (42.5%), 3.1-4.0 cm in 27 (23.9%), and >4.0 cm in 13 (11.5%). Nodal positivity was lower among patients with pT1 compared with pT2 tumors (8% vs 31%, P = .035) but did not differ across pT2 subgroups (P = .864). Twelve patients (10.6%) received chemotherapy, with nodal status determining treatment in only 2 cases. Regional nodal irradiation was administered to 15 of 37 patients with pathologically node-positive disease and omitted in the remainder. At the median follow-up of 3.1 years, 9 patients (8%) experienced recurrence; all pathologically node-positive patients with recurrence (n = 4) demonstrated endocrine therapy noncompliance. CONCLUSION: In women ≥65 years with cT2N0 hormone receptor-positive/human epidermal growth factor receptor-negative breast cancer, sentinel lymph node biopsy infrequently influenced adjuvant management. Chemotherapy was guided by genomic assays, and most patients with pathologically node-positive disease did not receive regional nodal irradiation, supporting a selective, individualized approach to axillary staging.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Khan MT, Wright GP, Thompson J, et al. Limited impact of sentinel lymph node biopsy in older women with cT2N0 hormone-positive human epidermal growth factor receptor 2-negative breast cancer. Surgery. 2026. PMID: 42810879. doi:10.1016/j.surg.2026.110626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。